TrialLancet (London, England)2022

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Grace Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.